There is provided a newly identified B7 receptor, zB7R1, which functions as lymphocyte inhibitory receptor. zB7R1 is a PD-1-like molecule expressed on T cells, and is able to bind to CD155. Methods and compositions for modulating zB7R1-mediated negative signalling and interfering with the interaction of its counter-receptor for therapeutic, diagnostic, and research purposes are also provided.